UCB stock weighs BIMZELX joint gains against Candida caveat

UCB said on Monday, November 9, that BIMZELX maintained higher joint-response rates than risankizumab through Week 24 in the Phase 3b BE BOLD trial. The company presented the full findings at the ACR Convergence in Orlando on Tuesday, November 10, according to its BE BOLD release.

Joint response remains ahead

At Week 24, 54.9% of patients receiving bimekizumab achieved an ACR50 response, compared with 43.8% for risankizumab. The Week 24 comparison was exploratory, while the primary Week 16 endpoint had already shown statistically significant superiority for bimekizumab, with ACR50 responses of 49.1% versus 38.0% and a p-value of 0.0058.

The trial enrolled 553 adults with active psoriatic arthritis in a randomized, double-blind comparison. UCB said responses across secondary endpoints remained numerically higher with bimekizumab, but sequential testing stopped after the first ranked secondary endpoint, leaving later comparisons descriptive.

Safety limits the read-through

Overall treatment-emergent adverse events occurred in 58.1% of bimekizumab-treated patients and 55.3% of those receiving risankizumab. Localized Candida infections were more frequent with bimekizumab at 2.9% versus 0.7%; UCB said all cases were mild or moderate, with none serious, systemic or leading to discontinuation. The company also said the trial was not powered for a formal safety comparison.

UCB stock traded at 291.65 euros on Lang & Schwarz at 18:35 CET on Wednesday, November 11, 2026.

Current market reports cover wider European trading.

More news and analyses on UCB stock